1. Home
  2. TECH vs RVPH Comparison

TECH vs RVPH Comparison

Compare TECH & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TECH
  • RVPH
  • Stock Information
  • Founded
  • TECH 1976
  • RVPH 2006
  • Country
  • TECH United States
  • RVPH United States
  • Employees
  • TECH N/A
  • RVPH N/A
  • Industry
  • TECH Biotechnology: Biological Products (No Diagnostic Substances)
  • RVPH Biotechnology: Pharmaceutical Preparations
  • Sector
  • TECH Health Care
  • RVPH Health Care
  • Exchange
  • TECH Nasdaq
  • RVPH Nasdaq
  • Market Cap
  • TECH 7.8B
  • RVPH 32.8M
  • IPO Year
  • TECH 1989
  • RVPH N/A
  • Fundamental
  • Price
  • TECH $53.14
  • RVPH $0.37
  • Analyst Decision
  • TECH Buy
  • RVPH Strong Buy
  • Analyst Count
  • TECH 11
  • RVPH 5
  • Target Price
  • TECH $72.00
  • RVPH $9.00
  • AVG Volume (30 Days)
  • TECH 2.2M
  • RVPH 2.6M
  • Earning Date
  • TECH 08-06-2025
  • RVPH 08-13-2025
  • Dividend Yield
  • TECH 0.60%
  • RVPH N/A
  • EPS Growth
  • TECH N/A
  • RVPH N/A
  • EPS
  • TECH 0.83
  • RVPH N/A
  • Revenue
  • TECH $1,208,770,000.00
  • RVPH N/A
  • Revenue This Year
  • TECH $7.07
  • RVPH N/A
  • Revenue Next Year
  • TECH $5.64
  • RVPH N/A
  • P/E Ratio
  • TECH $64.02
  • RVPH N/A
  • Revenue Growth
  • TECH 4.72
  • RVPH N/A
  • 52 Week Low
  • TECH $46.01
  • RVPH $0.30
  • 52 Week High
  • TECH $83.62
  • RVPH $4.28
  • Technical
  • Relative Strength Index (RSI)
  • TECH 59.96
  • RVPH 30.28
  • Support Level
  • TECH $49.89
  • RVPH $0.35
  • Resistance Level
  • TECH $53.95
  • RVPH $0.83
  • Average True Range (ATR)
  • TECH 1.89
  • RVPH 0.07
  • MACD
  • TECH 0.30
  • RVPH -0.04
  • Stochastic Oscillator
  • TECH 85.38
  • RVPH 11.32

About TECH Bio-Techne Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

About RVPH Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.

Share on Social Networks: